898562-93-1

Basic information

• Product Name: 2-[4-(2-METHYL-4-PYRIDIN-4-YL-2H-PYRAZOL-3-YL)-PHENOXYMETHYL]-QUINOLINE
• Synonyms: 2-[4-(2-METHYL-4-PYRIDIN-4-YL-2H-PYRAZOL-3-YL)-PHENOXYMETHYL]-QUINOLINE
• CAS NO: 898562-93-1
• Molecular Formula: C25H20N4O
• Molecular Weight: 0
• Mol File: 898562-93-1.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-[4-(2-METHYL-4-PYRIDIN-4-YL-2H-PYRAZOL-3-YL)-PHENOXYMETHYL]-QUINOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-[4-(2-METHYL-4-PYRIDIN-4-YL-2H-PYRAZOL-3-YL)-PHENOXYMETHYL]-QUINOLINE(898562-93-1)
• EPA Substance Registry System: 2-[4-(2-METHYL-4-PYRIDIN-4-YL-2H-PYRAZOL-3-YL)-PHENOXYMETHYL]-QUINOLINE(898562-93-1)

Safety Data

• Hazardous Substances Data: 898562-93-1(Hazardous Substances Data)

Upstream product

• 871507-11-8 2-((4-(4-(pyridin-4-yl)-1H-pyrazol-5-yl)phenoxy)methyl)quinoline 
• 60-34-4 methylhydrazine 
• 99-76-3 methyl 4-hydroxylbenzoate 
• 134138-88-8 4-(quinolin-2-ylmethyloxy)benzoyl chloride 
• 137426-86-9 4-(2-Quinolinylmethoxy)benzoic acid methyl ester 
• 123724-16-3 4-(quinolin-2-ylmethyloxy)benzoic acid 
• 871507-15-2 2-pyridin-4-yl-1-[4-(quinolin-2-ylmethoxy)-phenyl]-ethanone 
• 871507-14-1 N-methoxy-N-methyl-4-(quinolin-2-ylmethoxy)-benzamide 
• 4377-41-7 2-Chloromethylquinoline 
• 871507-16-3 3-(dimethylamino)-2-(pyridin-4-yl)-1-(4-(quinolin-2-ylmethoxy)phenyl)prop-2-en-1-one 

Relevant articles and documents

METHODS FOR TREATING DISEASES OF THE RETINA

Disclosed herein is a method of treating disorders of the retina comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of Formula I as defined herein. These compounds are useful as PDE10 inhibitors.

Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3- yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia

By utilizing structure-based drug design (SBDD) knowledge, a novel class of phosphodiesterase (PDE) 10A inhibitors was identified. The structure-based drug design efforts identified a unique "selectivity pocket" for PDE10A inhibitors, and interactions within this pocket allowed the design of highly selective and potent PDE10A inhibitors. Further optimization of brain penetration and drug-like properties led to the discovery of 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920). This PDE10A inhibitor is the first reported clinical entry for this mechanism in the treatment of schizophrenia.